Let me make a quick observation. Yes, the technology is getting cheaper in one way, but while the technology is getting cheaper, the networks that you need to actually put it into commercially viable platforms are getting more expensive. It's more industrially controlled, and the major cost in most developments is not the R and D cost anyway. If you really want to look at it, it's 10¢ for R and D and 90¢ for commercialization. So the costs could go almost to zero on the R and D side and you're still going to have the bulk of the costs. That's why you're seeing a scaling up and a consolidation within the global biotech business. We've gone to three companies having 97% market share because the regulatory system makes it so that only three companies can make any money in the business. And it's not just our regulatory system; it's the global system.
On October 5th, 2010. See this statement in context.